Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients

The COVID-19 pandemic continues to be a worldwide health issue. Among hemodialysis (HD) patients, two-dose immunization schemes with mRNA vaccines have contributed to preventing severe COVID-19 cases; however, some have not produced a sufficient humoral response, and most have developed a rapid decline in antibody levels over the months following vaccination. This observational, prospective, multi-center study evaluated the humoral response in terms of presence and levels of IgG antibodies to the receptor-binding domain of the S1 spike antigen of SARS-CoV-2 (anti-S1-RBD IgG) to the third dose of SARS-CoV-2 mRNA vaccines, either the mRNA-1273 (Moderna) or BNT162b2 (Pfizer), in 153 patients from three dialysis units affiliated to Hospital Clínic of Barcelona (Spain). Most hemodialysis patients responded intensely to this third vaccine dose, achieving the seroconversion in three out of four non- or weak responders to two doses. Moreover, 96.1% maintained the upper limit or generated higher titers than after the second. BNT162b2 vaccine, active cancer, and immunosuppressive treatment were related to a worse humoral response. Every hemodialysis patient should be administered a third vaccine dose six months after receiving the second one. Despite the lack of data, immunosuppressed patients and those with active cancer may benefit from more frequent vaccine boosters.

[1]  A. Hatzakis,et al.  Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study , 2022, Vaccines.

[2]  C. Balotta,et al.  Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility , 2022, Vaccines.

[3]  F. Diekmann,et al.  Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients , 2022, Journal of Nephrology.

[4]  P. Shitrit,et al.  Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients , 2022, Journal of Nephrology.

[5]  F. Maduell,et al.  Antibody maintenance and breakthrough infections 6 months after complete COVID-19 vaccination with the mRNA-1273 and BNT162b2 vaccines in hemodialysis patients , 2021, Clinical kidney journal.

[6]  K. Nedeltchev,et al.  Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis , 2021, Vaccines.

[7]  L. Pickering,et al.  Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer , 2021, Cancer Cell.

[8]  L. Juillard,et al.  A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis , 2021, Kidney International.

[9]  P. von Landenberg,et al.  Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study , 2021, Journal of clinical medicine.

[10]  T. Bachelet,et al.  Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times , 2021, PloS one.

[11]  K. Lhotta,et al.  Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost , 2021, Kidney International.

[12]  Zheng Wang,et al.  The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study , 2021, The Lancet Microbe.

[13]  M. Preusser,et al.  Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations. , 2021, JAMA oncology.

[14]  F. Maduell,et al.  Antibody maintenance 3 months after complete messenger RNA COVID-19 vaccination in haemodialysis patients , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  J. Chinen,et al.  Secondary immunodeficiencies. An overview. , 2021, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[16]  V. Caudwell,et al.  SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis , 2021, American Journal of Kidney Diseases.

[17]  F. Maduell,et al.  Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in haemodialysis patients. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  G. Piccoli,et al.  Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis , 2021, Clinical kidney journal.

[19]  T. Tonn,et al.  Cellular and Humoral Immune Responses After 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant , 2021, Transplantation.

[20]  C. Courivaud,et al.  Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis , 2021, Kidney International.

[21]  F. Maduell,et al.  Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients , 2021, American Journal of Kidney Diseases.

[22]  L. Rénia,et al.  COVID-19 vaccines and kidney disease , 2021, Nature Reviews Nephrology.

[23]  J. Dogné,et al.  Antibody titres decline 3-month post-vaccination with BNT162b2 , 2021, Emerging microbes & infections.

[24]  E. Montagud-Marrahi,et al.  SARS-CoV-2 Infection in a Spanish Cohort of CKD-5D Patients: Prevalence, Clinical Presentation, Outcomes, and De-Isolation Results , 2020, Blood Purification.

[25]  F. Maduell,et al.  Prevalence of COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening. , 2020, Journal of the American Society of Nephrology : JASN.

[26]  P. Kelleher,et al.  High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening. , 2020, Journal of the American Society of Nephrology : JASN.

[27]  Junhua Li,et al.  Lessons from the Experience in Wuhan to Reduce Risk of COVID-19 Infection in Patients Undergoing Long-Term Hemodialysis. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[28]  T. Eleftheriadis,et al.  Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patients. , 2014, World journal of gastroenterology.

[29]  L. Bracci,et al.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer , 2013, Cell Death and Differentiation.

[30]  D. Abramowicz,et al.  Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[31]  T. Eleftheriadis,et al.  Basic Science and Dialysis: Disturbances of Acquired Immunity in Hemodialysis Patients , 2007, Seminars in dialysis.

[32]  A. Pani,et al.  Immunosuppressive treatment in dialysis patients. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  J. Bargman,et al.  Continued transplant immunosuppression may prolong survival after return to peritoneal dialysis: results of a decision analysis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  OUP accepted manuscript , 2021, Nephrology Dialysis Transplantation.